Compare Stocks: PRFX, GLMD, UPC, and SXTP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GLMD Galmed Pharmaceuticals	$0.60 +3.3%	$0.58	$0.41 ▼ $1.65	$3.95M	0.74	1.60 million shs	13,022 shs
PRFX PainReform	$1.10	$1.44	$0.97 ▼ $17.95	$956K	1.06	1.50 million shs	59,040 shs
SXTP 60 Degrees Pharmaceuticals	$1.15 -5.7%	$1.52	$1.05 ▼ $8.62	$3.06M	2.54	1.94 million shs	48,428 shs
UPC Universe Pharmaceuticals	$6.24 +1.3%	$4.28	$2.00 ▼ $17.96	$3.51M	1.52	885,805 shs	88,821 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GLMD Galmed Pharmaceuticals	+1.22%	+3.63%	+4.13%	-7.42%	-63.75%
PRFX PainReform	-2.65%	+11.00%	-20.86%	-42.11%	-83.66%
SXTP 60 Degrees Pharmaceuticals	-0.81%	-18.12%	-27.38%	-22.78%	-77.90%
UPC Universe Pharmaceuticals	-12.62%	+88.96%	+2.67%	+105.33%	+71.59%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GLMD Galmed Pharmaceuticals	$0.60 +3.3%	$0.58	$0.41 ▼ $1.65	$3.95M	0.74	1.60 million shs	13,022 shs
PRFX PainReform	$1.10	$1.44	$0.97 ▼ $17.95	$956K	1.06	1.50 million shs	59,040 shs
SXTP 60 Degrees Pharmaceuticals	$1.15 -5.7%	$1.52	$1.05 ▼ $8.62	$3.06M	2.54	1.94 million shs	48,428 shs
UPC Universe Pharmaceuticals	$6.24 +1.3%	$4.28	$2.00 ▼ $17.96	$3.51M	1.52	885,805 shs	88,821 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GLMD Galmed Pharmaceuticals	+1.22%	+3.63%	+4.13%	-7.42%	-63.75%
PRFX PainReform	-2.65%	+11.00%	-20.86%	-42.11%	-83.66%
SXTP 60 Degrees Pharmaceuticals	-0.81%	-18.12%	-27.38%	-22.78%	-77.90%
UPC Universe Pharmaceuticals	-12.62%	+88.96%	+2.67%	+105.33%	+71.59%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GLMD Galmed Pharmaceuticals	1.00	Sell	N/A	N/A
PRFX PainReform	1.00	Sell	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	2.00	Hold	$13.85	1,104.35% Upside
UPC Universe Pharmaceuticals	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest PRFX, GLMD, UPC, and SXTP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/29/2026	UPC Universe Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	GLMD Galmed Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	PRFX PainReform	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/14/2026	UPC Universe Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/29/2026	UPC Universe Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/24/2026	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
5/22/2026	SXTP 60 Degrees Pharmaceuticals	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$4.20 ➝ $3.70
5/20/2026	SXTP 60 Degrees Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral

(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GLMD Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	$2.88 per share	N/A
PRFX PainReform	$17K	56.23	N/A	N/A	$23.07 per share	0.05
SXTP 60 Degrees Pharmaceuticals	$1.41M	2.17	N/A	N/A	($5.85) per share	-0.20
UPC Universe Pharmaceuticals	$17.74M	0.20	N/A	N/A	$99.64 per share	0.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GLMD Galmed Pharmaceuticals	-$10.31M	-$0.91	N/A	N/A	N/A	N/A	-35.32%	-30.94%	8/6/2026 (Estimated)
PRFX PainReform	-$5.02M	-$736.66	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	-$7.36M	-$8.92	N/A	N/A	N/A	-574.91%	N/A	-131.48%	8/12/2026 (Estimated)
UPC Universe Pharmaceuticals	-$3.67M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest PRFX, GLMD, UPC, and SXTP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	SXTP 60 Degrees Pharmaceuticals	-$0.74	N/A	N/A	N/A	$0.19 million	N/A
8/6/2026	N/A	GLMD Galmed Pharmaceuticals	-$0.39	N/A	N/A	N/A	N/A	N/A
7/29/2026	Q2 2026	UPC Universe Pharmaceuticals	N/A	-$1.38	N/A	-$1.38	N/A	$4.52 million
5/15/2026	Q1 2026	SXTP 60 Degrees Pharmaceuticals	-$0.76	-$1.28	-$0.52	-$1.28	$0.44 million	$0.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GLMD Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PRFX PainReform	N/A	N/A	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UPC Universe Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GLMD Galmed Pharmaceuticals	N/A	7.71	7.71
PRFX PainReform	N/A	1.78	1.78
SXTP 60 Degrees Pharmaceuticals	N/A	3.34	2.85
UPC Universe Pharmaceuticals	0.04	4.05	3.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GLMD Galmed Pharmaceuticals	76.14%
PRFX PainReform	37.28%
SXTP 60 Degrees Pharmaceuticals	7.96%
UPC Universe Pharmaceuticals	0.18%

Insider Ownership

Company	Insider Ownership
GLMD Galmed Pharmaceuticals	19.80%
PRFX PainReform	34.40%
SXTP 60 Degrees Pharmaceuticals	1.68%
UPC Universe Pharmaceuticals	57.38%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GLMD Galmed Pharmaceuticals	20	6.60 million	5.29 million	Not Optionable
PRFX PainReform	4	869,000	570,000	Not Optionable
SXTP 60 Degrees Pharmaceuticals	3	2.66 million	2.61 million	Not Optionable
UPC Universe Pharmaceuticals	220	563,000	240,000	N/A

PRFX, GLMD, UPC, and SXTP Headlines

Recent News About These Companies

Universe Pharmaceuticals Earnings Estimates, EPS & Revenue | NASDAQ:UPC

July 18, 2026 | benzinga.com

Universe Pharmaceuticals INC - Ordinary Shares - Class A

July 17, 2026 | money.usnews.com

Universe Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:UPC | Benzinga

June 29, 2026 | benzinga.com

4 Sizzling Biotech and Healthcare Companies Reporting Strategic Milestones

June 29, 2026 | markets.businessinsider.com

China's Universe Pharmaceuticals (NASDAQ: UPC) Makes Nasdaq Top Gainer List on Acquisition News

June 29, 2026 | investorideas.comI

Universe Pharmaceuticals INC.: Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio

June 27, 2026 | finanznachrichten.de

Universe Pharmaceuticals Inc

June 26, 2026 | fool.com

UPC stock surges 288% after hours — what’s driving the rally?

June 26, 2026 | msn.com

Universe Pharmaceuticals to acquire Best Praise for $10.75M

June 26, 2026 | seekingalpha.com

Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio

June 26, 2026 | globenewswire.com

Universe Pharmaceuticals Stock News

June 17, 2026 | benzinga.com

Hologic Secures Significant Patent Victory Against Siemens Over Breast Cancer Detection Technology

June 16, 2026 | businesswire.com

Universe Pharmaceuticals Incorporation Class A

April 29, 2026 | edition.cnn.com

Universe Pharmaceuticals (NASDAQ:UPC) Stock Price Down 2.4% â€“ Time to Sell?

April 25, 2026 | defenseworld.netD

Universe Pharmaceuticals Sets February 13 Effective Date for Dual-Class Share Structure

February 11, 2026 | tipranks.com

Universe Pharmaceuticals INC Implements Dual-Class Share Structure on Nasdaq Effective February 13, 2026

February 11, 2026 | quiverquant.comQ

Universe Pharmaceuticals INC Announces Effective Date of Dual-Class Share Structure

February 11, 2026 | globenewswire.com

Universe Pharmaceuticals Inc trading resumes

October 8, 2025 | msn.com

Universe Pharmaceuticals Inc trading halted, volatility trading pause

October 8, 2025 | msn.com

Universe Pharmaceuticals Approves Key Resolutions at 2025 AGM

September 3, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PRFX, GLMD, UPC, and SXTP Company Descriptions

Galmed Pharmaceuticals NASDAQ:GLMD

$0.60 +0.02 (+3.28%)

Closing price 04:00 PM Eastern

Extended Trading

$0.60 +0.01 (+1.00%)

As of 05:14 PM Eastern

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

PainReform NASDAQ:PRFX

$1.10 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.13 +0.03 (+2.64%)

As of 05:25 PM Eastern

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

60 Degrees Pharmaceuticals NASDAQ:SXTP

$1.15 -0.07 (-5.74%)

Closing price 03:59 PM Eastern

Extended Trading

$1.16 +0.01 (+0.43%)

As of 04:24 PM Eastern

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

Universe Pharmaceuticals NASDAQ:UPC

$6.24 +0.08 (+1.30%)

Closing price 04:00 PM Eastern

Extended Trading

$6.04 -0.21 (-3.29%)

As of 05:13 PM Eastern

Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRFX, GLMD, UPC, and SXTP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRFX, GLMD, UPC, and SXTP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRFX, GLMD, UPC, and SXTP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PRFX, GLMD, UPC, and SXTP Company Descriptions

Galmed Pharmaceuticals NASDAQ:GLMD

PainReform NASDAQ:PRFX

60 Degrees Pharmaceuticals NASDAQ:SXTP

Universe Pharmaceuticals NASDAQ:UPC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRFX, GLMD, UPC, and SXTP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRFX, GLMD, UPC, and SXTP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRFX, GLMD, UPC, and SXTP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PRFX, GLMD, UPC, and SXTP Company Descriptions

Galmed Pharmaceuticals NASDAQ:GLMD

PainReform NASDAQ:PRFX

60 Degrees Pharmaceuticals NASDAQ:SXTP

Universe Pharmaceuticals NASDAQ:UPC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools